Galectin Therapeutics stock falls 2.22 percent as trial advances
Published on 09/24/2026 at 23:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Galectin Therapeutics stock fell 2.22 percent to USD 3.96 on Nasdaq on September 24, 2026, leaving the biotechnology company 44.46 percent below its 52-week high of USD 7.13. The move came as investors weighed belapectin's advance toward Phase III testing and the financial demands of the next development stage.
Belapectin advances toward Phase III
At a September 14, 2026 conference presentation, Galectin Therapeutics outlined a path toward registration testing for belapectin in MASH cirrhosis with portal hypertension. Investing.com reported that the NAVIGATE Phase IIb study showed a 43.2 percent reduction in new varices for the 2 milligram group versus placebo.
The same report said the trial recorded zero drug-related serious adverse events and no drug-induced liver injury. That combination gives the program a clear clinical narrative, but Phase III data will carry the larger validation burden.
Quarterly loss raises funding pressure
MarketBeat said the company reported a quarterly loss of USD 0.14 per share against USD 0.09 expected. The USD 0.05 per-share shortfall adds a financial counterweight to the clinical progress.
Galectin also presented at the H.C. Wainwright conference after announcing the event on September 10, 2026. GlobeNewswire said management would present and hold one-on-one meetings during the September 14-16 event.
Stock remains below yearly high
Galectin Therapeutics stock was trading at USD 3.96 on Nasdaq on September 24, 2026, with a market capitalization of USD 260,793,316. Its 52-week range was USD 2.03 to USD 7.13, so the current price sits materially closer to the yearly low than the yearly high.
Galectin Therapeutics stock facts
- Company: Galectin Therapeutics Inc.
- Ticker: GALT
- Trading venue: Nasdaq
- Price (September 24, 2026): USD 3.96
- Market capitalization: USD 260,793,316 (September 24, 2026)
- 52-week range: USD 2.03-7.13 (September 24, 2026)
- Sector / Industry: Healthcare / Biotechnology
